Amanda Nerstad, Program Coordinator at Survivor Fitness Foundation, Operations Manager at Interiors by Jen Davidson, shared a post on LinkedIn:
“ASCO Abstract 8517 is now public, highlighting the ARCHER ALK vaccine trial led by Dr. Vincent Lam and team, with encouraging early results for the ALK+ community.
Honored to be part of this research as Patient 2 in the trial.
Dr. Lam will present the data at ASCO, an incredible honor and reflection of the importance of this work.”
Title: Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trial.
Authors: Michael R. Conroy, Yuxuan Wang, Bert Vogelstein, Joseph C. Murray, Kristen A. Marrone, Susan C. Scott, Josephine L. Feliciano, Christine L. Hann, Christopher Thoburn, Aliyah Pabani, Patrick M. Forde, Chen Hu, Neeha Zaidi, Julie Nauroth, Julie R. Brahmer, Valsamo Anagnostou, Benjamin P. Levy, Kellie N. Smith, Mark Yarchoan, Vincent K. Lam
Read the Full Article.
Other articles featuring Amanda Nerstad on OncoDaily.